Keymed, Biosciences Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM 07.08.2025 - 18:04:54 Keymed China View original content:https://www.prnewswire.co.uk/news-releases/keymed-biosciences-announces-safety-and-efficacy-results-of-cm313-for-primary-immune-thrombocytopenia-published-in-nejm-302177732.html
